

Contents

Series Editors Preface *xiii*

Preface *xv*

1	CNS Drug Discovery in “The Century of Biology”	1
	<i>Dario Doller</i>	
	Acronyms	1
1.1	Welcome to “The Century of Biology”!	1
1.2	Understanding Brain Health Around the World	2
1.3	Where Are New CNS Drugs Coming from?	3
1.4	Psychedelics as Potential Therapeutic Drugs	5
1.5	CNS Drugs Acting at Novel Biological Targets	8
1.6	Starting with the End in Mind: Defining a CNS Disease	9
1.7	Where to Go from Here	11
	References	13
2	Advances in Disease Modifying Therapies for Parkinson’s Disease	17
	<i>Kambiz Hassanzadeh and M. Maral Mouradian</i>	
	Acronyms	17
2.1	Introduction	18
2.2	Parkinson’s Disease Pathology	18
2.2.1	Protein Aggregation and Propagation	18
2.2.2	Genetics of Parkinson’s Disease	19
2.3	Disease-Modifying Treatments for Parkinson’s Disease	21
2.3.1	α -Synuclein Targeting	21
2.3.1.1	Immunization	21
2.3.1.2	Reducing α -Synuclein Expression	25
2.3.1.3	Inhibition of α -Synuclein Aggregation	29
2.3.1.4	Enhancing Clearance and Degradation of α -Synuclein	31
2.3.2	Targeting Non-receptor Tyrosine Kinases c-Abl	33
2.3.3	Glucocerebrosidase Targeting	36
2.3.4	Leucine-Rich Repeat Kinase 2 Targeting	40
2.3.5	Targeting Other Players	41
2.3.5.1	Targeting Glucagon-like Peptide-1	41
2.3.5.2	Anti-Apoptotic and Antioxidant Agents	42
2.3.5.3	Myeloperoxidase Inhibitors	42

2.3.5.4	Targeting of α -Syn Post-Translational Modifications	42
2.4	Progress and Challenges	44
	References	45
3	Psychedelics-Inspired Drug Discovery	67
	<i>Alan Gibbs and Tanweer Khan</i>	
	Acronyms	67
3.1	Introduction	68
3.2	What Are Psychedelics and What Makes a Compound, Psychedelic?	69
3.3	What Is Known about the Therapeutic Mechanism of Action of Psychedelics?	69
3.4	Typical Psychedelics	70
3.4.1	The Receptors	70
3.4.2	The Compounds	72
3.5	Non-psychedelic Serotonergic Agonists	75
3.6	Atypical Psychedelics	77
3.6.1	κ -Opioid Receptor (KOR) Agonists Act as Dissociatives	77
3.6.2	N-Methyl-D-Aspartate Receptor (NMDA) Antagonists Are Dissociative Anesthetics	78
3.6.3	γ -Aminobutyric Acid (GABA _A) Receptor Agonists Are Hypnotic Dissociatives	79
3.6.4	Muscarinic Acetylcholine Receptor (mAChR Aka Cholinergic Receptor) Antagonists May Act as Deliriants	79
3.7	Psychoactive Cannabinoids as Atypical Psychedelics	80
3.7.1	What Are Cannabinoids?	80
3.7.2	Cannabinoids as Therapeutics	81
3.7.3	Current and Future Cannabinoid Research	82
3.8	Conclusion	82
	References	83
4	Epilepsy and Related Seizure Disorders	91
	<i>Jovanna A. Tracz and Alberto E. Musto</i>	
	Acronyms	91
4.1	Introduction	92
4.1.1	What Is a Seizure?	92
4.1.2	Epilepsy	93
4.1.2.1	Definition	93
4.1.2.2	Classification	93
4.1.3	Medical Management Strategies for Epilepsy	94
4.1.3.1	Present Medical Management in Clinical Practice	94
4.1.3.2	Initiation and Monitoring of ASM	97
4.1.3.3	Patient Response to Anti-Seizure Medication	97
4.2	Models and Mechanisms of Drug-Resistant Epilepsy	98
4.2.1	In Vitro Models of Drug-Resistant Epilepsy	98
4.2.1.1	Low Magnesium Extracellular Concentrations	98
4.2.1.2	4-Aminopyridine	98
4.2.1.3	Mimicking Additional Components Contributing to Pharmacoresistance	99
4.2.1.4	Patient-Derived Embryonic and Induced Pluripotent Stem Cells	99
4.2.2	In Vivo Models of Drug-Resistant Epilepsy	99

4.2.3	Proposed Mechanisms of Drug Resistance	100
4.3	Targets for Drug Development	100
4.3.1	History of Epilepsy Drug Development	100
4.3.2	Mechanisms of Action in Novel Drug Targets under Investigation	100
4.3.2.1	Modulators of Voltage-Gated Sodium Channels	101
4.3.2.2	Reduction of T-Type Voltage-Gated Calcium Channel Activity	103
4.3.2.3	Activators of Voltage-Gated Potassium Channels	104
4.3.2.4	Modulation of Neurotransmission	104
4.3.2.5	Regulation of Synaptic Vesicle Proteins	106
4.3.2.6	Targeting the Immune System	106
4.3.2.7	Gene Therapy	106
4.3.2.8	Epigenetic Modification	106
4.3.2.9	Modulators of Synaptic Plasticity	106
4.3.2.10	Other	106
4.4	Future Challenges in Epilepsy Drug Development	107
	Acknowledgments:	108
	References	108
5	Strategies for Neuroprotection in Alzheimer's Disease	117
	<i>Hilary Grosso Jasutkar</i>	
	Acronyms	117
5.1	Introduction	118
5.2	Targeting Pathogenic Protein Aggregation	120
5.2.1	A β	121
5.2.1.1	Immunotherapy Against A β	121
5.2.1.2	A β Cleavage	124
5.2.2	Tau	125
5.2.2.1	Immunotherapy Against Tau	125
5.2.2.2	Gene Therapies	125
5.2.2.3	Modulation of Tau Post-translation Modifications	126
5.2.2.4	Microtubule Stabilization	127
5.3	Oxidative Stress and Mitochondrial Dysfunction	128
5.4	Neuroinflammation	130
5.5	Protein Processing Pathways	130
5.5.1	Autophagy	131
5.6	Conclusions	132
	References	133
6	Rigor in Experimental Design in Nonregulated Preclinical Research in Neuroscience Drug Discovery	141
	<i>Sara Steele, Anton Beshpalov, and Els Dequeker</i>	
	Acronyms	141
6.1	Introduction	141
6.2	What Makes Data Robust?	142
6.2.1	Experimental Design Features to Improve Internal Validity	142
6.2.1.1	Randomization	143
6.2.1.2	Blinding	144
6.2.1.3	Exclusion Criteria	145
6.2.1.4	Sex as a Biological Variable (SABV)	145

6.3	Other Types of Validity and Poor Translatability	145
6.4	Threats to Robust Data	147
6.4.1	Underpowered Studies	147
6.4.2	Questionable Research Practices	148
6.4.3	Reporting Bias	149
6.4.4	Lack of Preregistration	150
6.4.5	Research Misconduct	151
6.5	Reporting Standards	151
6.6	Animal Welfare	154
6.7	Regulated Versus Nonregulated Nonclinical Studies	154
6.7.1	GLP Studies	154
6.7.2	Non-GxP Studies	155
6.8	Conclusion	155
	References	155
7	Biomarkers in CNS Drug Discovery, Drug Development, and Clinical Implementation	161
	<i>Valentina Di Caro, Claire Williams, Hilary A. North, and Mary E. Hamby</i>	
	Acronyms	161
7.1	Introduction	162
7.2	Biomarkers in Drug Discovery, Development, and Clinical Implementation	164
7.2.1	Biomarker Types and Applications	164
7.2.2	Life Cycle of a Biomarker: From Preclinical Discovery to Clinical Development	168
7.2.2.1	Preclinical Biomarker Discovery	168
7.2.2.2	Biomarkers in Clinical Trials	170
7.2.2.3	The Importance of Validation and Qualification	171
7.3	Biomarkers for Alzheimer's Disease: History and Overview	172
7.3.1	History and Progress in Diagnostic Biomarkers for AD	172
7.3.2	Use of Diagnostic and Potential Surrogate Biomarkers to Facilitate Regulatory Approval for AD	173
7.4	Pharmacodynamic and Candidate Surrogate Biomarkers for AD	174
7.4.1	Core AD Biomarkers: A β and Tau	175
7.4.2	The Importance of Biomarkers of Synaptic Health and Function	177
7.4.3	Established Synaptic Biomarkers	179
7.4.4	Exploratory Synaptic Biomarkers	179
7.4.5	Inflammation-Related Biomarkers	180
7.4.6	Biomarkers of Vascular Dysfunction	181
7.5	Discovering New Biomarkers for AD: An Ongoing Need	182
7.5.1	Identifying New Biomarkers Through Discovery Proteomics	182
7.6	Case Study: Example of Successful Discovery of New Candidate Biomarkers Through Proteomics in the SHINE-A Clinical Cohort	184
7.6.1	SHINE-A Use of Biomarkers to Demonstrate Target or Pathway Engagement in a Clinical Trial	184
7.6.2	SHINE-A Use of Surrogate Biomarkers of Disease Modification	185
7.7	Advancements in Biomarker Discovery and Development for Neurodegenerative Diseases Beyond AD	186

7.8	Conclusions and Future Directions	189
	References	189
8	Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) in CNS Drug Discovery	199
	<i>Benny Bang-Andersen and Hanne Demant Garling</i>	
	Acronyms	199
8.1	Introduction	200
8.1.1	PET Imaging in Drug Discovery	200
8.1.2	The Early Drug Discovery Situation	201
8.2	PET Imaging in Clinical Drug Development	201
8.2.1	Proof of Distribution (PoD)	201
8.2.2	Proof of Occupancy (PoO)	203
8.2.2.1	Designing Target Occupancy Studies	204
8.2.2.2	Quantifying Target Occupancy	205
8.2.3	Proof of Mechanism (PoM)	205
8.2.3.1	Magnetic Resonance Imaging (MRI) and Hybrid PET/MRI	207
8.3	PET Radioligand Discovery and Development	208
8.3.1	Considerations Before Initiating a CNS PET Radioligand Discovery Project	208
8.3.2	Small Molecule CNS PET Radioligand Design Parameters	209
8.3.3	PET Radioligand Stage-Gates from Hits to Clinical PET Radioligand	210
8.3.3.1	Hit-Finding Phase: Radioligand Hits	210
8.3.3.2	Hit-to-Lead Phase: Radioligand Leads	211
8.3.3.3	Lead Optimization Phase: Preclinical Radioligand	211
8.3.3.4	Clinical PET Radioligand Candidate	212
8.3.3.5	Clinical PET Radioligand	212
8.3.4	Emerging Application of Immuno-PET for CNS Imaging	212
8.4	Conclusion	218
	References	218
9	Bioanalytical Strategies to De-risk CNS Drug Discovery for Novel Chemical Modalities	229
	<i>Scott G. Summerfield, David A. Fairman, and James W.T. Yates</i>	
	Acronyms	229
9.1	Introduction	230
9.2	Permeation of Molecules into the Brain: Key Compartments and Processes	230
9.3	Key Considerations for Novel Chemical and Biological Constructs	234
9.4	A Brief History of the $K_{p,uu}$ Concept and Its Importance for CNS-Focused Drug Design	238
9.5	Moving Beyond the Rule-of-5 and Newer Territory for CNS Drugs	239
9.6	Understanding Analytical Errors and Variability in Brain Penetration Measurements	241
9.7	Potential Bioanalytical Technologies for Novel Modalities	243
9.8	Bioanalytical Approaches to Account for Brain Concentration and Brain Vascular Volume	244
9.9	Measuring Target Engagement	246

9.10	Summary and Conclusions	247
	References	247
10	Discovery of ABBV-951 (VYALEV™/PRODUODOPA®) for Advanced Parkinson's Disease	255
	<i>Eric A. Voight, Matthew R. Rosebraugh, and Philip R. Kym</i>	
	Acronyms	255
10.1	Introduction	255
10.2	Synthesis of Levodopa and Carbidopa Phosphate Prodrugs	257
10.2.1	Levodopa-4'-monophosphate (Foslevodopa) Synthesis	258
10.2.2	Carbidopa-4'-monophosphate (Foscarbidopa) Synthesis	259
10.3	Preclinical Characterization	260
10.3.1	Solubility and Stability	260
10.3.2	Bioconversion	261
10.3.3	Preclinical Safety	263
10.4	Clinical First-in-Human and Phase 1 Studies	263
10.4.1	First-in-human ABBV-951 Study	263
10.4.2	First in Patient ABBV-951 Study	266
10.5	Conclusions	268
	References	268
11	Inducers of Targeted Protein Degradation as Drug Candidates for Neurodegenerative Disorders	273
	<i>Shusuke Tomoshige and Minoru Ishikawa</i>	
	Acronyms	273
11.1	Introduction	274
11.1.1	Protein Degradation Machinery	274
11.1.2	Targeted Protein Degradation Using Hetero-bifunctional Molecules	277
11.1.3	Molecular Glue Degraders	279
11.1.4	Feasibility of TPD-Based Drugs to Treat Neurodegenerative Disorders (NDs)	280
11.2	PROTACs for NDs	281
11.2.1	Peptide-Based PROTACs	281
11.2.2	Small-Molecule PROTACs Targeting Protein Aggregates	282
11.2.3	Small-Molecule PROTACs Targeting Specific NDs-Related Proteins	290
11.3	Hydrophobic Tagging for the Treatment of NDs	290
11.4	Approaches Exploiting Lysosomal Degradation for Treatment of NDs	291
11.5	Other TPD Strategies for the Treatment of NDs	295
11.6	Availability of TPD Drugs in the CNS	296
11.6.1	Drug-Likeness of Degraders: The Greatest Obstacle to the Discovery of TPD-Based CNS Drugs	296
11.6.2	CNS Availability of Degraders	298
11.7	Summary and Outlook	303
	References	303
12	Kinase Inhibitors for the Treatment of Brain Diseases	311
	<i>Chenzhong Liao, Qin Wang, and Zhouling Xie</i>	
	Acronyms	311
12.1	Introduction	312
12.1.1	Brain Diseases	312
12.1.2	Brain Tumors	313

12.1.3	The Development of Kinase Inhibitors	314
12.2	Kinase Inhibitors for the Treatment of Brain Tumors	316
12.2.1	Kinases with Approved Inhibitors for Brain Tumors	316
12.2.1.1	B-Rapidly Accelerated Fibrosarcoma (BRAF)	316
12.2.1.2	Mammalian Target of Rapamycin (mTOR)	317
12.2.1.3	Epidermal Growth Factor Receptor (EGFR)	319
12.2.1.4	Anaplastic Lymphoma Kinase (ALK)	323
12.2.2	Potential Kinases for the Treatment of Brain Tumors	325
12.3	Kinase Inhibitors for the Treatment of Nononcologic Brain Diseases	333
12.3.1	Kinases with Approved Inhibitors for the Treatment of Nononcologic Brain Diseases	333
12.3.1.1	mTOR	333
12.3.1.2	Rho-Associated Protein Kinases (ROCKs)	334
12.3.2	Kinases with Potential Inhibitors for the Treatment of Nononcologic Brain Diseases	335
12.3.2.1	Breakpoint Cluster Region-Abelson (BCR-ABL)	335
12.3.2.2	p38 Mitogen-Activated Protein Kinases (p38 MAPKs)	336
12.3.2.3	Dual Leucine Zipper Kinase (DLK) and Leucine Zipper-bearing Kinase (LZK)	337
12.3.2.4	Mixed Lineage Kinase 3 (MLK3)	338
12.3.2.5	LRRK2	339
12.3.2.6	Glycogen Synthase Kinase 3 (GSK3)	340
12.3.2.7	Receptor Interacting Protein Kinase 1 (RIPK1)	340
12.3.3	Miscellaneous	341
12.4	Perspectives	342
12.4.1	Physicochemical Differences Between Approved CNS Drugs and Brain-Penetrant Kinase Inhibitors	342
12.4.2	Conclusions: Current Challenges in Developing Kinase Inhibitors to Treat Brain Diseases	343
12.4.3	Strategies to Develop Kinase Inhibitors to Treat Brain Diseases	343
	References	345
13	An Academic Laboratory's Approach for Discovering CNS-Active Drug-Like Small Molecules for the Treatment of SMA	353
	<i>Kevin J. Hodgetts, Anne Rietz, and Elliot J. Androphy</i>	
	Acronyms	353
13.1	Introduction	353
13.2	Design of a Library of Riluzole Analogs	360
13.2.1	Chemistry	360
13.2.2	Results	361
13.3	Conclusions	371
	References	372
14	Medicinal Chemistry "in the System": A CNS Drug Design Narrative Fit for the Century of Biology	377
	<i>Dario Doller</i>	
	Acronyms	377
14.1	Introduction: Like Biology, Drug Design Is Getting More Complex	377
14.2	Allosteric Modulation: Transitioning from a Two-Particle to a Three-Particle System	378

14.3	Orthosteric Drug or Allosteric Drug?	380
14.4	Examples of Allosteric Modulators Progressing in the Clinic for CNS Indications	385
14.5	Can Allosteric Functional Effects Be Predicted? The Five Dimensions of Protein Function	391
14.6	Allosteric Binding Sites: Examples of Allosteric Function	394
14.7	Beyond Allosterism: Progress Toward Drug Discovery “in a system”	396
14.8	Non-small Molecule Therapeutics for CNS Disorders	399
14.9	Summary and a Look Ahead	402
	References	403
15	The Role of Venture Capital in Drug Discovery	411
	<i>Arthur J. Hiller</i>	
	Acronyms	411
15.1	Introduction	411
15.2	Sources of Funding: Focusing on the Best Path for Future Success	414
15.3	Your Company’s Value Proposition	418
15.4	Identifying Key Stakeholders to Ensure Product Adoption	419
15.5	The Role of Market Definition in Defining the Discovery Opportunity	419
15.6	Leverage Points in the Buying Process	422
15.7	Understanding the Competitive Landscape	423
15.8	The Benefit Ladder	425
15.9	Developing and Refining the Business Model	427
15.10	Building the Team to Take You to the Finish Line	427
15.11	The Current Investment Landscape in Neurology	428
15.12	A Bright Future for Neuroscience Investment	432
	References	434
	Further Reading	437
16	Epilog: CNS Drug Discovery – The Years Ahead	439
	<i>Dario Doller</i>	
	Acronyms	439
16.1	The Dual Frontier: AI and the Human Brain in CNS Drug Discovery	439
16.2	The Rate of CNS Drug Discovery and Reaction Kinetics Theory	441
16.3	AI Can Discover Novel Drugs (Under the Right Conditions)	445
16.4	An Example of What AI Cannot Do: Autoantibody Receptor Encephalitis	447
16.5	The Limitations of Artificial Intelligence in CNS Drug Discovery	449
16.6	Conclusion: Toward a Brighter Tomorrow	451
	References	451
	Index	455